Week 2 of Wegovy with no weight loss — what's actually happening

What the STEP 1 trial tells us about the early weeks

The pivotal trial for Wegovy, published in the New England Journal of Medicine, enrolled over 1,900 adults and ran for 68 weeks. The headline figure (around 15% average body-weight reduction) reflects what happened across the full course of treatment. The study was not designed to show dramatic losses in the opening days. Participants started at 0.25mg, the same place every Wegovy patient begins, and dose escalation followed a structured four-weekly schedule up to 2.4mg maintenance. Weight loss tracked the dose upward: slow and modest at first, then more pronounced as the therapeutic dose was reached and held.

That pattern matters when you are standing on the scales in week 2 and seeing no movement. The evidence simply does not support expecting visible results this early. Looking at how your body responds over months, rather than days, is consistent with how the medicine was studied and licensed.

The NHS medicines page for semaglutide reflects this: it describes a gradual titration and notes that the full effect of the medicine takes time to establish. That is not a caveat buried in small print, it is central to how the treatment works.

Why the scales in week 2 can mislead you

Several things happen in the first two weeks that affect what you see when you weigh yourself, independent of fat loss. GI side effects (nausea, looser stools, changes in how quickly food moves through) are common at this stage. They alter fluid balance. Starting any calorie-reduced eating pattern also causes a transient drop in glycogen stored in muscle, and glycogen holds water; that water loss often appears in the first week of Wegovy, when many people notice an initial shift that can partly reverse as the body adjusts, making it look as though progress has stalled or reversed when it has not.

Weighing conditions vary too. The same person can show a kilogram of difference between a morning weigh-in after a full night's sleep and an evening reading after meals and fluids. If you weighed yourself under different conditions than you did in week 1, the comparison may not be meaningful.

None of this is unique to Wegovy. It is a feature of early weight-management treatment that our prescribers see reflected in the questions patients raise. Tracking a weekly average (same time, same day, same conditions) gives a steadier signal than any single reading.

If your experience in week 2 has you wondering how the results typically develop over time, our page on how weight loss on Wegovy tends to progress covers the data in more depth.

What week 2 with no change does not mean

It does not mean Wegovy is not working. It does not mean you are an exception. And (this is the point patients tell us they wish they had heard earlier) it does not mean you need to push ahead with a dose increase to speed things along. Increasing the dose outside the licensed schedule, or stopping abruptly because week 2 felt flat, are both decisions that carry clinical risk and should only happen with a prescriber's input.

It also does not mean a complete absence of change in your body. Semaglutide begins acting on GLP-1 receptors from the first injection; the appetite signals, the slower gastric emptying, the reduced drive to eat between meals, these effects start earlier than the scales reflect. The medicine is working even when the number does not move.

For many people, the first noticeable scale drop comes somewhere between weeks 4 and 8, once the dose has increased, and what people typically see by week 5 gives a more realistic picture of where results start to become meaningful. Our page on how long Wegovy typically takes to work sets out what the evidence suggests at each stage. If you are heading into week 3 still without movement, it is worth reading through what the evidence says for week 3 as well.

When to talk to your prescriber rather than wait

Most people in week 2 with no weight loss simply need patience and consistent habits alongside the medicine: adequate protein, enough water, some activity. If, however, you are experiencing side effects that are making eating or drinking difficult (persistent vomiting, signs of dehydration, or stomach pain that does not settle) speak to your prescriber or GP rather than adjusting anything yourself. Severe or persistent abdominal pain that radiates to the back should be assessed promptly; the MHRA has highlighted acute pancreatitis as an infrequent but serious concern with GLP-1 medicines, and it warrants urgent medical attention. You can also report any suspected side effects through the MHRA Yellow Card scheme.

If your situation is more about reassurance than a clinical concern, the fuller picture of why some people see no weight loss on Wegovy (and what can be done) is a good next read. And if you are exploring whether Wegovy is appropriate for you in the first place, our free consultation connects you with a GPhC-registered prescriber who reviews your case the same day. No algorithm, no automated output, a real clinician reads your answers, usually before the school-run cut-off if you submit by midday.